Home › Funds › Palo Alto Investors LP › NAMS
Palo Alto Investors LP position in NAMS
NEWAMSTERDAM PHARMA COMPANY · Health Care
Palo Alto Investors LP reported holding 162,874 shares of NAMS (NEWAMSTERDAM PHARMA COMPANY) in its Q3 2026 13F filing — a position valued at US$4.0M, representing 0.59% of its reported portfolio and ranking #29 among its reported holdings. Palo Alto Investors LP has disclosed NAMS holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Palo Alto Investors LP's NAMS position evolved
Palo Alto Investors LP first disclosed a stake in NAMS in Q2 2026 at 44,359 shares (US$1.5M). The position peaked in Q3 2026 at 162,874 shares, worth US$4.0M. Across 2 filings, Palo Alto Investors LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 162,874 shares valued at US$4.0M — an increase of 118,515 shares quarter over quarter.. Notable position changes include a 267% increase in Q3 2026 (shares fell 20% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 44.36K | $1.50M | New |
| Q3 2026 | 162.87K | $3.96M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NAMS and 13F data
NAMS (NEWAMSTERDAM PHARMA COMPANY) is a Health Care company. 35 other funds we track also report a position in NAMS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$461.8M), RA CAPITAL MANAGEMENT, L.P. (US$232.3M), FCPM III SERVICES B.V. (US$206.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NAMS
- Frazier Life Sciences Management, L.P. 18.99M sh · $461.81M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 9.55M sh · $232.26M · Q3 2026
- FCPM III SERVICES B.V. 8.49M sh · $206.49M · Q3 2026
- Maverick Capital 3.27M sh · $110.75M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 4.25M sh · $103.46M · Q3 2026
- Bain Capital Life Sciences Investors, LLC 3.81M sh · $92.58M · Q3 2026
- Duquesne Family Office LLC 3.36M sh · $81.65M · Q3 2026
- Medicxi Ventures Management (Jersey) Ltd 2.18M sh · $53.07M · Q3 2026
- MAVERICK CAPITAL LTD 1.86M sh · $45.13M · Q3 2026
More on Palo Alto Investors LP
FAQ
How long has Palo Alto Investors LP held NAMS?
Palo Alto Investors LP has disclosed NAMS holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Palo Alto Investors LP's current position in NAMS?
As of Q3 2026, Palo Alto Investors LP holds 162.87K shares of NAMS (NEWAMSTERDAM PHARMA COMPANY), valued at $3.96M, representing 0.59% of its reported portfolio and ranking #29.
Has Palo Alto Investors LP been buying or selling NAMS?
In the latest 13F filing (Q3 2026), Palo Alto Investors LP increased its position in NAMS. The position peaked in Q3 2026 at 162.87K shares.
Which other funds hold NAMS?
Other major institutional holders of NAMS include Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., FCPM III SERVICES B.V., among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.